未登录

B

Brian Lu

University of Alabama at Birmingham

H指数:24

被引数:2,365

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of a Diabetes Subtype Classification Model Using Data from U.S. Adults Before and After the COVID-19 Pandemic

使用COVID-19大流行前后美国成年人数据验证糖尿病亚型分类模型

IF3.7

2026-03-190

OA

Data-driven Cluster Analysis Reveals Increased Risk for Severe Insulin-deficient Diabetes in Black/African Americans

数据驱动的聚类分析显示，黑人/非裔美国人患严重胰岛素缺乏糖尿病的风险增加

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2024-07-301

OA

Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2024-02-221

OAAI

Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling

IF7.5

2023-07-266

OA

Verapamil Prevents Decline of IGF-1 in Subjects with T1D

IF7.5

2023-06-200

PRE

Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-03-066

OAAI

Alpha Cell Thioredoxin-interacting Protein Deletion Improves Diabetes-associated Hyperglycemia and Hyperglucagonemia

IF3.3

2022-08-123

OA

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study (vol 11, 696512, 2021)

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-071

OAAI

The UVSSA protein is part of a genome integrity homeostasis network with links to transcription-coupled DNA repair and ATM signaling

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2022-03-073

OAAI

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

选择性组蛋白去乙酰化酶抑制剂ACY-241 (西司他丁) 联合Nivolumab治疗晚期非小细胞肺癌: Ib期研究结果

FRONTIERS IN ONCOLOGY

IF3.3

2021-09-0626

OAAI

Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-07-2316

OAAI

Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2021-04-035

PRE

Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)

ANNALS OF ONCOLOGY

IF65.4

2020-11-010

OAAI

Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action

CELL METABOLISM

IF30.9

2020-09-0167

OAAI

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix

JOURNAL OF CLINICAL INVESTIGATION

IF13.6

2020-08-0484

OA

Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

BREAST CANCER RESEARCH AND TREATMENT

IF3

2020-05-0437

OAAI

Effect of Topical Brimonidine on Alcohol-Induced Flushing in Asian Individuals A Randomized Clinical Trial

JAMA DERMATOLOGY

IF11

2020-02-014

OAAI

Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes

DISEASE MODELS & MECHANISMS

IF3.3

2018-06-1323

OAAI

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

IF3.4

2017-12-2214

OAAI

Gene length as a biological timer to establish temporal transcriptional regulation

IF3.4

2017-01-1223

OAAI